Gastric sleeve revision for GORD is an increasingly important consideration for patients who develop persistent or worsening reflux following sleeve gastrectomy. Whilst sleeve gastrectomy is one of the most commonly performed bariatric procedures in the UK, its anatomical changes can significantly increase gastro-oesophageal reflux disease risk in a substantial proportion of patients. When lifestyle modifications and proton pump inhibitor therapy fail to control symptoms, conversion to Roux-en-Y gastric bypass (RYGB) is the most evidence-supported revisional option. This article explains why sleeve gastrectomy can worsen GORD, when revision is appropriate, what the procedure involves, and how to discuss your options with your bariatric team.

Why Gastric Sleeve Surgery Can Worsen or Cause GORD

Sleeve gastrectomy raises intragastric pressure, disrupts the angle of His, and may reduce lower oesophageal sphincter competence, all of which promote gastro-oesophageal reflux in a substantial proportion of patients.

Gastric sleeve surgery, formally known as sleeve gastrectomy, involves removing approximately 75–80% of the stomach to create a narrow, tube-shaped pouch. Whilst this procedure is highly effective for weight loss, it carries a well-documented association with gastro-oesophageal reflux disease (GORD, also referred to as GERD in some international literature).

The anatomical changes introduced by sleeve gastrectomy can contribute to reflux through several mechanisms:

• Reduced gastric compliance: The smaller, tubular stomach generates higher intragastric pressure, which can force stomach contents upward into the oesophagus.

• Disruption of the angle of His: This natural anti-reflux barrier at the gastro-oesophageal junction is often altered during the procedure, reducing its protective function.

• Reduced lower oesophageal sphincter (LES) pressure: Anatomical changes may impair the competence of the LES, facilitating reflux of both acid and bile.

• Altered gastric emptying: Sleeve gastrectomy typically accelerates gastric emptying; however, in cases of sleeve torsion or functional obstruction, delayed emptying may occur and increase reflux risk.

• Hiatus hernia: Pre-existing or newly identified hiatus hernias are associated with sleeve gastrectomy and can significantly worsen reflux symptoms.

Published meta-analyses and position statements from the International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO) suggest that a substantial proportion of patients — estimates vary widely across studies — experience new-onset or worsening GORD following sleeve gastrectomy, with some reporting symptoms refractory to standard medical management. In a subset of patients, oesophageal complications such as oesophagitis or, in severe cases, Barrett's oesophagus may develop over time.

It is important to note that endoscopic surveillance is not routinely recommended for all symptomatic patients. In line with NICE guideline NG1 (Gastro-oesophageal reflux disease and dyspepsia in adults), endoscopy is indicated for patients with alarm features or persistent symptoms despite treatment. Ongoing surveillance for Barrett's oesophagus follows British Society of Gastroenterology (BSG) criteria and applies specifically to patients with a confirmed Barrett's diagnosis. Understanding the physiological basis of post-sleeve GORD is essential when considering whether revision surgery may be appropriate.

When Revision Surgery Is Recommended for GORD

Revision surgery is considered when GORD is refractory to optimised PPI therapy, when endoscopy shows Grade C/D oesophagitis or Barrett's oesophagus, or when quality of life is substantially impaired; RYGB conversion is the preferred approach.

Not every patient who experiences reflux after a gastric sleeve will require revision surgery. Initial management follows a stepwise approach aligned with NICE guideline NG1, beginning with lifestyle modifications and pharmacological therapy.

First-line measures include:

• Lifestyle changes: weight management, avoiding late meals, elevating the head of the bed, reducing alcohol and caffeine intake, and smoking cessation

• Alginate-based preparations (e.g., Gaviscon) for symptomatic relief

• A trial of full-dose proton pump inhibitor (PPI) therapy — such as omeprazole or lansoprazole — for at least eight weeks. PPIs work by irreversibly inhibiting the hydrogen-potassium ATPase enzyme in gastric parietal cells, thereby reducing acid secretion

• H2-receptor antagonists may be used as adjuncts where PPI response is incomplete

Urgent assessment is required if you develop dysphagia (difficulty swallowing), unexplained weight loss, vomiting, or signs of gastrointestinal bleeding such as dark or tarry stools. These are red-flag symptoms that should prompt urgent GP review and may warrant a two-week suspected cancer referral in line with NICE guideline NG12 (Suspected cancer: recognition and referral).

Revision surgery is considered when:

• Symptoms are refractory to optimised medical therapy, including full-dose PPIs and H2-receptor antagonists

• Endoscopic findings reveal progressive oesophagitis (Grade C or D on the Los Angeles classification), Barrett's oesophagus, or significant hiatus hernia

• Quality of life is substantially impaired, with persistent nocturnal reflux, regurgitation, or aspiration risk

• Inadequate weight loss or weight regain accompanies GORD, making a revisional bariatric procedure doubly beneficial

The most widely performed and evidence-supported revision in this context is conversion from sleeve gastrectomy to Roux-en-Y gastric bypass (RYGB). The RYGB configuration diverts bile and pancreatic secretions away from the oesophagus and creates a small gastric pouch with a lower acid-producing capacity, significantly reducing reflux burden. In selected patients with a significant hiatus hernia but otherwise manageable reflux, targeted hiatal hernia repair with or without sleeve revision may be considered; however, RYGB conversion is generally preferred for refractory GORD because it addresses both acid and bile reflux. BOMSS and international bariatric guidelines broadly support RYGB conversion as the preferred revisional strategy in this setting.

Patients should undergo thorough pre-operative assessment, including upper GI endoscopy. Where the diagnosis is uncertain or prior to revisional surgery, high-resolution oesophageal manometry and 24-hour pH/impedance monitoring should be considered as clinically indicated, in line with BSG and AGIP guidance. Cross-sectional imaging (CT) is reserved for specific clinical indications such as suspected anatomical complications. Referral to a specialist bariatric centre with multidisciplinary team (MDT) input is essential before any revision is undertaken.

What to Expect Before, During, and After Revision Surgery

Pre-operative preparation includes nutritional assessment, endoscopy, and psychological evaluation; the procedure is performed laparoscopically and requires lifelong nutritional supplementation and structured post-operative monitoring.

Preparation for gastric sleeve revision surgery is comprehensive and typically more involved than the original bariatric procedure. Patients will undergo a structured pre-operative pathway that includes:

• Nutritional assessment by a specialist dietitian to identify and correct deficiencies common after sleeve gastrectomy, including iron, vitamin B12, vitamin D, calcium, folate, thiamine, and vitamins A and K. Pre-operative H. pylori testing and eradication should be considered in line with local pathways

• Psychological evaluation to ensure readiness for the lifestyle demands of a revised anatomy

• Cardiorespiratory assessment, particularly relevant in patients with obesity-related comorbidities

• Endoscopy and targeted investigations as outlined above, tailored to individual clinical need

• Contraception and pregnancy counselling: women of childbearing age should be advised to avoid pregnancy for at least 12–18 months following revisional surgery, in line with BOMSS guidance

The revision procedure itself — most commonly conversion to RYGB — is performed laparoscopically in the majority of cases, though the presence of adhesions from prior surgery can increase operative complexity and duration. The surgeon creates a small gastric pouch (typically 15–30 ml) from the remaining stomach and connects it directly to a limb of the small intestine, bypassing the remnant stomach and proximal bowel. This fundamentally alters the digestive pathway and eliminates the high-pressure sleeve environment that drives reflux.

Patients should be advised to stop smoking and avoid NSAIDs before and after surgery, as both significantly increase the risk of marginal ulceration. A short course of PPI therapy post-operatively is commonly prescribed as prophylaxis, in line with local protocols.

The post-operative recovery period mirrors that of a primary RYGB. Patients typically remain in hospital for two to three days and are commenced on a staged dietary progression — from fluids to purées to soft foods — over four to six weeks. Lifelong nutritional supplementation is mandatory following RYGB. In line with BOMSS postoperative monitoring guidance, this typically includes a complete multivitamin and mineral supplement, calcium with vitamin D, iron, and vitamin B12; thiamine supplementation is recommended where clinically indicated. Blood tests to monitor nutritional status should be performed at three, six, and twelve months post-operatively, then annually thereafter, using the test panel recommended by BOMSS. Most patients report significant improvement in GORD symptoms within weeks of surgery, though full resolution may take several months.

Risks, Benefits, and Long-Term Outcomes of Sleeve Revision

RYGB conversion carries risks including anastomotic leak, stricture, and nutritional deficiencies, but evidence consistently shows significant GORD improvement or resolution in the majority of patients following conversion.

As with any revisional surgical procedure, conversion from sleeve gastrectomy to RYGB carries a higher risk profile than primary bariatric surgery. Patients and clinicians must weigh these risks carefully against the potential benefits.

Key risks include:

• Anastomotic leak, which may require further intervention; rates vary by centre and are reported in the National Bariatric Surgery Registry (NBSR)

• Stricture formation at the gastrojejunal anastomosis, presenting as dysphagia or food intolerance

• Nutritional deficiencies, which are more pronounced after RYGB than sleeve gastrectomy and require lifelong supplementation and monitoring

• Dumping syndrome, characterised by nausea, palpitations, and diarrhoea following rapid gastric emptying, particularly after high-sugar or high-fat foods

• Marginal ulceration, especially in patients who smoke or use NSAIDs post-operatively; PPI prophylaxis is commonly prescribed

• Internal hernia and small bowel obstruction, a recognised long-term complication of RYGB that may present with acute abdominal pain and requires prompt assessment

• Venous thromboembolism (VTE), mitigated by appropriate pharmacological and mechanical prophylaxis in the peri-operative period

• Bleeding, both intra-operatively and from anastomotic sites in the post-operative period

Modifiable risk factors — including smoking and NSAID use — should be addressed before and after surgery to reduce complication rates.

Despite these risks, the evidence base for RYGB conversion in the context of refractory post-sleeve GORD is encouraging. Systematic reviews and observational data consistently demonstrate significant improvement or resolution of GORD in the majority of patients following conversion, with many able to reduce or discontinue PPI therapy. It should be noted that some patients continue to require ongoing acid suppression, and outcomes vary between individuals and centres. Additional benefits include renewed or sustained weight loss, improved glycaemic control in patients with type 2 diabetes, and enhanced quality of life.

Long-term outcomes are generally favourable when patients adhere to dietary guidance and attend regular follow-up. Barrett's oesophagus, if present pre-operatively, requires ongoing endoscopic surveillance in line with BSG guideline intervals even after successful revision, as regression is not guaranteed.

All patients undergoing bariatric revision surgery should be managed within NHS England Tier 4 commissioned specialist centres, regulated by the Care Quality Commission (CQC) and participating in the National Bariatric Surgery Registry (NBSR), to ensure appropriate governance and safety standards are maintained.

If you experience any suspected side effects from medicines prescribed as part of your care, you can report these via the MHRA Yellow Card Scheme at yellowcard.mhra.gov.uk.

Talking to Your Surgical Team About GORD After Bariatric Surgery

Patients should promptly report persistent reflux, dysphagia, unexplained weight loss, or gastrointestinal bleeding to their GP or bariatric team, as these symptoms may require urgent assessment and possible two-week cancer referral under NICE NG12.

Open and informed communication with your bariatric surgical team is central to achieving the best outcome when GORD develops or worsens after a gastric sleeve. Many patients are reluctant to report persistent reflux symptoms, either assuming they are an inevitable consequence of surgery or fearing further intervention. However, untreated or inadequately managed GORD can lead to serious oesophageal complications, and early discussion with your team is always encouraged.

In the meantime, interim self-care measures — such as using alginate preparations (e.g., Gaviscon), elevating the head of the bed, avoiding meals within two to three hours of lying down, and bringing a full list of your current medications to your appointment — can help manage symptoms and assist your team in reviewing your care.

You should contact your GP or bariatric team promptly if you experience:

• Persistent heartburn or regurgitation that is not controlled by prescribed medication

• Difficulty swallowing (dysphagia) or painful swallowing (odynophagia)

• Unexplained weight loss, persistent vomiting, or signs of gastrointestinal bleeding such as dark or tarry stools

• Nocturnal symptoms that disturb sleep or cause coughing and hoarseness

• Any new or worsening symptoms following a period of stability

Seek urgent GP assessment if you develop dysphagia, unexplained weight loss, or signs of gastrointestinal bleeding. These symptoms may warrant a two-week suspected cancer referral in line with NICE guideline NG12, and should not be delayed.

When attending your appointment, it is helpful to keep a symptom diary noting the frequency, severity, and triggers of your reflux episodes, as well as your current medication regimen. This information assists your team in determining whether medical optimisation is sufficient or whether further investigation and revision surgery should be considered.

Your bariatric MDT — comprising a surgeon, dietitian, specialist nurse, and psychologist — will guide you through the decision-making process in a balanced, patient-centred manner. There is no single correct pathway, and the decision to proceed with revision surgery should be made collaboratively, with a clear understanding of the expected benefits and risks. Reliable information is available through NHS GORD (acid reflux) pages, BOMSS patient resources, and the European Association for Endoscopic Surgery (EAES) clinical practice guidelines on bariatric and metabolic surgery, all of which support informed shared decision-making in this complex but manageable clinical scenario.

Frequently Asked Questions